upadacitinib,vedolizumab,natalizumab,ustekinumab
biogen,abbvie,takeda,janssen
[' vedo', ' upa ', 'vedo', 'crohn', 'ustekinumab', 'natalizumab', 'vedolizumab']
 with #upa data on previous biologic exposed #cd the key message is whether patient had prior tnfi or not makes difference #ecco2023 
IBD clinician& researcher @IBDHull.Chair:Research Committee of @BritSocGastro . Chair of ECCO CLiNCOM. @NIHR (Y&H ) lead. own views ,RT🚫endorse.⚽️ @LFC fan.